CA Patent

CA2908815A1 — Drug combinations to treat cancer

Assigned to Exelixis Inc · Expires 2014-10-09 · 12y expired

What this patent protects

This invention relates to the combination of cabozantinib and abiraterone to treat cancer, particularly castration resistant prostate cancer.

USPTO Abstract

This invention relates to the combination of cabozantinib and abiraterone to treat cancer, particularly castration resistant prostate cancer.

Drugs covered by this patent

Patent Metadata

Patent number
CA2908815A1
Jurisdiction
CA
Classification
—
Expires
2014-10-09
Drug substance claim
No
Drug product claim
No
Assignee
Exelixis Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.